Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: Candidacy for systemic treatment or clinical trials

Journal of Vascular and Interventional Radiology

Volumn 24, Issue 8, 2013, Pages 1189-1197.e2

  Memon, Khairuddin ^a   Kulik, Laura ^a   Lewandowski, Robert J ^a   Gupta, Ramona ^a   Ryu, Robert K ^a   Miller, Frank H ^a   Vouche, Michael ^a   Atassi, Rohi ^a   Ganger, Daniel ^a   Mulcahy, Mary F ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; YTTRIUM 90;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER THERAPY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COURSE EVALUATION; EARLY CANCER; EMBOLIC PARTICLE; FEMALE; FOLLOW UP; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOEMBOLIZATION; SYSTEMIC THERAPY; TUMOR NECROSIS;

BARCELONA CLINIC LIVER CANCER; BCLC; EASL; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; HCC; HEPATOCELLULAR CARCINOMA; LOCOREGIONAL THERAPY; LRT; NATIONAL CLINICAL TRIALS; NCT; PD; PROGRESSIVE DISEASE; TIME TO PROGRESSION; TTP; UNITED NETWORK FOR ORGAN SHARING; UNOS; WHO; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TIME FACTORS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84880713859     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.12.025     Document Type: Article

References (26)

1. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
2. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
3. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
4. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
5. K. Memon, L. Kulik, and R.J. Lewandowski Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression J Hepatol 58 2013 73 80
6. R. Salem, R.J. Lewandowski, and L. Kulik Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 2011 497 507
7. R.J. Lewandowski, M.F. Mulcahy, and L.M. Kulik Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort Radiology 255 2010 955 965
8. R. Salem, and K.G. Thurston Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278
9. R. Salem, R.J. Lewandowski, and V.L. Gates Research reporting standards for radioembolization of hepatic malignancies J Vasc Interv Radiol 22 2011 265 278
10. D.M. Liu, R. Salem, and J.T. Bui Angiographic considerations in patients undergoing liver-directed therapy J Vasc Interv Radiol 16 2005 911 935
11. A. Forner, C. Ayuso, and M. Varela Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
12. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
13. A. Riaz, F.H. Miller, and L.M. Kulik Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069
14. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
15. A. Riaz, K. Memon, and F.H. Miller Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation J Hepatol 54 2011 695 704
16. S. Senthilnathan, K. Memon, and R.J. Lewandowski Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients Hepatology 55 2012 1432 1442
17. P. Hilgard, M. Hamami, and A.E. Fouly Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 2010 1741 1749
18. T. Livraghi, G. Brambilla, C. Carnaghi, M.A. Tommasini, and G. Torzilli Is it time to reconsider the BCLC/AASLD therapeutic flow-chart? J Surg Oncol 102 2010 868 876
19. K. Sato, R.J. Lewandowski, and J.T. Bui Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization Cardiovasc Intervent Radiol 29 2006 522 529
20. K.Y. Tam, K.C. Leung, and Y.X. Wang Chemoembolization agents for cancer treatment Eur J Pharm Sci 44 2011 1 10
21. R. Lencioni, X.P. Chen, L. Dagher, and A.P. Venook Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15 suppl 4 2010 42 52
22. K. Memon, L. Kulik, and R.J. Lewandowski Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times Gastroenterology 141 2011 526 535
23. G.K. Abou-Alfa, L. Schwartz, and S. Ricci Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 2006 4293 4300
24. G.K. Abou-Alfa, D. Amadori, and A. Santoro Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis Gastrointest Cancer Res 4 2011 40 44
25. J. Bruix, M. Reig, and J. Rimola Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques Hepatology 54 2011 2238 2244
26. C. Georgiades, J.F. Geschwind, and N. Harrison Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265 2012 115 123